Helix BioPharma Corp.

Presenter: John Docherty, President and COO

Company Profile

Helix BioPharma Corporation is developing innovative medicines mainly in the areas of cancer prevention and treatment.

Helix is focused on the development of two product candidates based on the company's two platform technologies, Biphasix and DOS47.

The Company's most advanced initiative, employing Helix's topical drug delivery system called Biphasix, is Topical Interferon Alpha-2b. It is in clinical development as a preventative therapeutic against cervical cancer as well as a treatment for ano-genital warts, both of which are conditions caused by human papillomavirus (HPV) infections.

Helixs second initiative is L-DOS47 for the treatment of the most common form of lung cancer, lung adenocarcinoma. L-DOS47 is based upon Helix's patented new broad spectrum therapeutic platform, called DOS47, for the destruction of cancer cells. L-DOS47 is in preclinical development in preparation for clinical testing.

Company Strategy

Helix discovers and develops therapeutics based on its two platform technologies, Biphasix for topical drug delivery of large molecules and DOS47, an agent that is toxic to cancer cells and can be coupled to highly specific targeting molecules.

Helix's strategy is to discover then move drug candidates into clinical development. It then searches for an appropriate partner to commercialize the drug. Helix also seeks collaborations to develop molecules incorporating Helix's core technologies.

Programs

Topical Interferon Alpha-2b is in Phase 2 clinical trials for the treatment of cervical dysplasia and ano-genital warts; both are caused by human papilloma infection. Helix plans to submit an IND to begin a Phase 2/3 trial in cervical dysplasia patients in the U.S. by mid calendar 2010.

L-DOS47 is in late preclinical development for the treatment of lung adenocarcinoma. Helix plans to submit an IND to begin a Phase 1 trial in the U.S. and a CTA to begin a Phase 1/2 trial in Europe by mid calendar 2010.

Management Team

Donald H. Segal, Ph.D., Chairman and CEO
John M. Docherty, M.Sc., President and COO
Frank Michalargias, CA,
Chief Financial Officer
Heman Chao, Ph.D., Chief Scientific Officer

Presenter Bio

Mr. Docherty has extensive multi-disciplinary experience in the pharmaceutical and biotechnology industries. John has been president and COO since 2007 and is responsible for overseeing the clinical development programs and managing the company's day-to-day operations. From 2002 to 2007, he was vice president of corporate development for Helix and was responsible for seeking out-licensing and in-licensing opportunities. John joined Helix in 1999 and he played an integral role in implementing the development plan for Topical Interferon Alpha-2b cream. Prior to joining Helix, John was a corporate and operational strategy consultant with PricewaterhouseCoopers Pharmaceutical Consulting Group.

Contact

Helix BioPharma Corp.
3-305 Industrial Parkway South
Aurora
Ontario, Canada
L4G 6X7

ph: 905-841-2300 ext. 286
fx: 905-841-2244

www.helixbiopharma.com
docherty@helixbiopharma.com

April 6-8, 2010